Tevogen Bio Holdings (TVGN)
NASDAQ:TVGN
Want to see TVGN full AI Analyst Report?
TVGN Stock Chart & Stats
$0.32
-$0.17(-11.18%)
At close: 4:00 PM EST
$0.32
-$0.17(-11.18%)
Day’s Range― - ―
52-Week Range$4.14 - $71.00
Previous CloseN/A
Volume2.03M
Average Volume (3M)557.82K
Market Cap
$39.91M
Enterprise Value$43.31M
Total Cash (Recent Filing)$692.30K
Total Debt (Recent Filing)$3.07M
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.84
Shares Outstanding4,219,343
10 Day Avg. Volume531,944
30 Day Avg. Volume557,817
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-6.68
Price to Sales (P/S)0.00
P/FCF Ratio-4.44
Enterprise Value/Market Cap1.09
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-299.01
Enterprise Value/Ebitda-2.08
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-10.14
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
T‑cell Immunotherapy PlatformTevogen's focus on precision CTL (T‑cell) therapies for infectious disease and cancer represents a durable, proprietary therapeutic approach. Platform-driven cell therapies can yield high barriers to entry, repeatable R&D pathways, and licensing or partnership optionality that support long-term value creation if clinical proof points are achieved.
Restored Nasdaq Bid‑price ComplianceSuccessfully restoring bid‑price compliance via a reverse split preserves the company’s Global Market listing, maintaining regulated market access and visibility. This structural stability supports future capital raises and institutional participation over the coming months, which is critical for funding ongoing R&D in biotech.
Declining Debt LevelsA materially reduced debt load improves near‑term solvency and reduces fixed financial obligations, providing more flexibility to allocate scarce capital toward clinical programs. Lower debt eases refinancing pressure and interest expense risk, which benefits the firm's runway and strategic options over the medium term.
Bears Say
No Revenue, Persistent LossesThe absence of revenue and ongoing operating losses create chronic funding dependency and dilution risk. Sustained negative profitability and cash burn (roughly $12M TTM) mean the company must access external capital to advance trials, limiting self‑funding capacity and making progress contingent on market financing conditions.
Negative Stockholders' EquityPersistent negative equity signals solvency strain and weak capitalization, constraining borrowing and strategic flexibility. It increases counterparty and investor concerns, can complicate future financings or partnerships, and materially raises the risk profile for sustaining operations absent significant external support.
Market‑value Nasdaq Non‑compliance RiskNasdaq notices for failing market‑value thresholds create a structural listing risk despite bid‑price compliance. Potential transfer to the Capital Market or delisting would reduce liquidity, hinder capital raises, and impair investor confidence, posing a material challenge to the company’s ability to fund and advance programs over the next several months.
Tevogen Bio Holdings News
TVGN FAQ
What was Tevogen Bio Holdings’s price range in the past 12 months?
Tevogen Bio Holdings lowest stock price was $4.13 and its highest was $71.00 in the past 12 months.
What is Tevogen Bio Holdings’s market cap?
Tevogen Bio Holdings’s market cap is $39.91M.
When is Tevogen Bio Holdings’s upcoming earnings report date?
Tevogen Bio Holdings’s upcoming earnings report date is Aug 13, 2026 which is in 52 days.
How were Tevogen Bio Holdings’s earnings last quarter?
Tevogen Bio Holdings released its earnings results on Jun 03, 2026. The company reported -$1.612 earnings per share for the quarter, beating the consensus estimate of -$2.64 by $1.028.
Is Tevogen Bio Holdings overvalued?
According to Wall Street analysts Tevogen Bio Holdings’s price is currently Overvalued.
Does Tevogen Bio Holdings pay dividends?
Tevogen Bio Holdings does not currently pay dividends.
What is Tevogen Bio Holdings’s EPS estimate?
Tevogen Bio Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tevogen Bio Holdings have?
Tevogen Bio Holdings has 4,219,343 shares outstanding.
What happened to Tevogen Bio Holdings’s price movement after its last earnings report?
Tevogen Bio Holdings reported an EPS of -$1.612 in its last earnings report, beating expectations of -$2.64. Following the earnings report the stock price went up 6.966%.
Which hedge fund is a major shareholder of Tevogen Bio Holdings?
Currently, no hedge funds are holding shares in TVGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tevogen Bio Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Sold Shares
Worth $6.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.20%
12-Months-Change
Fundamentals
Return on Equity
241.39%
Trailing 12-Months
Asset Growth
20.81%
Trailing 12-Months
Company Description
Tevogen Bio Holdings
Tevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology. Its flagship experimental product, TVGN 489, is a precision T cell therapeutic engineered to address critical unmet needs in patients with acute-risk COVID-19, alongside a specific population experiencing long COVID. The company's operations are headquartered in Warren, New Jersey.
Technical Analysis
Nkarta
―
C4 Therapeutics
―
Shattuck Labs
―
Nuvectis Pharma
―
Actuate Therapeutics, Inc.
―